Mapoka Ekurapwa

Kurapa Kwakakurumbira

Kurapa Nehutachiona hweOncolytic: Kurapa Kenza Kwepamusoro

CAR-T yeGlioblastoma

Jekiseni reNusinersen Sodium: Tariro yeKupera kweMutsipa weMusana

Kurapa kweCAR-T kweKenza yeMudumbu

Kurapa kweCAR-T kweNeuroblastoma Yakadzoka Pakarepo/Isingadzoreki

CAR-T yeSystemic Lupus Erythematosus (SLE)

Chirwere cheSickle Cell & Thalassemia

Kurapa Majini Kunopa Tariro Itsva kuVarwere veSickle Cell neThalassemia

FUCASO: Kurapa kweBCMA CAR-T kweVanhu Vakazara Nesimba Risina Kuenzana uye Kuchengetedzeka

Kubatanidza Masero eNK: Kufambira Mberi Kurapa Kenza Kupfuura Miganhu

0102030405

Pfupiso Yakakwana yeKurapwa KweLeukemia Kunotyisa

CAR-T Therapy, muchidimbu zvinoreva Chimeric Antigen Receptor T-Cell Immunotherapy, inzira yepamusoro yekurapa majini inosanganisira kugadzirisa majini emurwere T masero kuti arwise uye aparadze masero egomarara. Kusiyana nemishonga yechinyakare, CAR-T therapy yakagadzirirwa murwere wega wega uye inoda kuunganidza T masero kubva muropa remurwere asati adzoserwa mumuviri mushure mekugadzirwa kwemajini.

Taura nesu

Zviratidzo zveCAR-T

● B-cell acute lymphoblastic leukemia

●Multiple myeloma

●Leukemia isingaperi yelymphocytic

●Non-Hodgkin lymphoma

●Kupararira kweB-cell lymphoma yakakura

●SLE (Systemic Lupus Erythematosus)

●Myasthenia gravis

●Zvimwe zvirwere zve autoimmune

Kushanda zvakanaka kwekiriniki yeCAR-T

Zviratidzo zveCD19+20CAR-T: Varwere vane B-cell non Hodgkin's lymphoma

Mwedzi mumwe chete CR rate	Mutengo wePR wemwedzi mumwe chete	Mwedzi mumwe chete OR chiyero	CRS≥3	CRES≥3
71.95% (59/82)	25.6 (21/82)	97.55（80/82）	12.19% (10/82)	0

Zviratidzo zveCD19+22CAR-T: Kurapa kwevarwere vane chirwere cheCD19 vane chirwere cheB-lymphocytic leukemia chinodzoka shure uye chisingadzoreki

Mwedzi mumwe chete CR rate	Mutengo wePR wemwedzi mumwe chete	Mwedzi mumwe chete OR chiyero	CRS≥3	CRES≥3
92.1% (35/38)	7.9% (3/38)	100% (38/38)	15.79% (6/38)	0

Zviratidzo zveBCMACAR-T: Kurapa kwe multiple myeloma inodzokera shure uye isingadzoreki

Mwedzi mumwe chete CR rate	Mutengo wePR wemwedzi mumwe chete	Mwedzi mumwe chete OR chiyero	CRS≥3	CRES≥3
72.41% (21/29)	27.59% (8/29)	100% (29/29)	6.9% (2/29)	0

ZVIMWE ZVINOTAURWA NE CAR-T THERAPY (2)ch

Zvakanakira Zvedu

● Kurapwa Kwakasiyana Nevamwe: Kurapa kwega kwega kweCAR-T kwakagadzirirwa murwere, zvichiita kuti pave nemigumisiro yekurapa yakanangwa zvakanyanya uye inoshanda.

● Sarudzo Dzakasiyana-siyana dzeKutarisa: Nemhando dzakasiyana-siyana dzemaantigen anoshandiswa, anosanganisira CD7, CD19, CD20, CD22, uye BCMA, zvigadzirwa zvedu zveCAR-T zvinopa hunyanzvi hwakasiyana-siyana mukurapa kenza dzakasiyana-siyana dzeropa nezvirwere zve autoimmune.

● Kubudirira Kwakaratidzwa Kwekiriniki: Kurapa kwedu kweCAR-T kwakaratidza kushanda kwakanaka muzvirwere zvakawanda zvekurapa, nekuwedzera kwekuregererwa kwechirwere uye kuchengetedzeka, zvichisimbisa chinzvimbo chedu semutungamiri mukurapa nekudzivirira chirwere.

● Kubudirira Kwakanyanya Kwemari: Tinopa mukana wekukwikwidzana nekurapa kwemhando yepamusoro pamutengo uri nyore kana tichienzanisa nezvimwe zvigadzirwa zveCAR-T zviri pamusika.

● Tekinoroji Yemazuva Ano: Tichishandisa kufambira mberi kwazvino mukugadzira majini, marapirwo edu eCAR-T anosanganisira remangwana rekurapa kenza nezvirwere zve autoimmune.

● Rutsigiro rweNyanzvi dzeKliniki: Chikwata chedu chine ruzivo rwevanachiremba nevaongorori chinopa rubatsiro rwakakwana kubva pakubvunzana kwekutanga kuburikidza nekupa rubatsiro rwekurapa uye kutevera.

Masero eCAR-T ava kuzivikanwa zvakanyanya nekushanda kwawo zvakanaka muvarwere vasina kupindura kurapwa kwechinyakare senge chemotherapy kana kuisirwa mubofu. Vezvehutano pasi rose vanobvuma kugona kukuru kwekurapa kweCAR-T mukuchinja mhedzisiro yevarwere.

Zvidzidzo zvine chekuita nekurapa kweCAR-T uye nyaya

1. Kurapa kweCAR-T kweSystemic Lupus Erythematosus: Kushanda Kunoshamisa Munyaya Yevana

Nyaya itsva paErlangen University Hospital yakaratidza kushanda kweCAR-T cell therapy mukurapa musikana ane makore gumi nemashanu ane systemic lupus erythematosus (SLE). Mushure mekurapwa kwakawanda kwakundikana, Uresa akagamuchira mushonga uyu mutsva muna Chikumi 2023. Pakazosvika mavhiki matatu mushure mekurapwa, zviratidzo zvake zvakanga zvavandudzika zvakanyanya, zvichikonzera kupora kwakakwana uye kudzorerwa kwebasa reitsvo. Kubudirira uku ndiko kwekutanga kushandiswa kweCAR-T therapy yezvirwere zvevana zvinorwisa muviri, zvichiratidza kugona kwayo kuwana zororo kwenguva refu uye kushandura mhedzisiro yemurwere. Kumwe kutsvagurudza kuri kuitwa kuti kuongorore mashandisirwo ayo mumamiriro akafanana.

https://www.bioocus.com/news/breakthrough-in-pediatric-autoimmune-disease-car-t-cell-therapy-cures-lupus-patient/

2. Kurapa kweCAR-T kweMultiple Myeloma: Kurerutsirwa Kwakakosha Kwawanikwa

Bjørn Simensen, murwere wekuNorway ane makore 67 okuberekwa, akaona shanduko inoshamisa mukurwisa kwake multiple myeloma (IgG lambda, ISS-II) mushure mekugamuchira CAR-T cell therapy. Pakutanga akaonekwa muna 2017, akaongororwa kakawanda, asi akadzokera shure muna 2021. Mushure mekurapwa kusina kushanda, akatumirwa kuLu Daopei Hospital muna Kukadzi 2022, kwaakasarudzwa kuti arapwe neCAR-T therapy. Mushure mekurapwa, CAR-T cells dzake dzakaiswa. Pakazosvika zuva rechi28, kuongororwa kwakatevera kwakaratidza kuti hapana plasma cells dzisina kujairika mubone morrow yake, zvichiratidza kubudirira kukuru mukurapwa kwake.

https://www.bioocus.com/bj-rn-simensen-multiple-myeloma-igg-lambda-iss-ii-product/

3. Kurapa kweCD7 CAR-T kweT-ALL neLBL yakadzoka: Kushanda Kwakanaka uye Migumisiro

Ongororo ichangobva kuitwa inoratidza kushanda kweCD7 chimeric antigen receptor T-cell (CAR-T) therapy pamwe chete ne allogeneic hematopoietic stem cell transplantation (HSCT) kune varwere vane relapsed T-cell acute lymphoblastic leukemia (T-ALL) uye lymphoblastic lymphoma (LBL). Chidzidzo ichi chakaitwa paHebei Yanda Lu Daopei Hospital, chakabatanidza varwere gumi nevatanhatu vakawana relievement inoshamisa ye100% minimal residual disease (MRD)-negative complete relieve mushure mekurapwa. Ne75% complete relieve rate ye extramedullary loses uye gore rimwe chete rekurarama uye leukemia-free leukemia rates ye58.5% ne51.4%, zvichiteerana, nzira iyi itsva inopa tariro itsva yerelieve yenguva refu mune idzi cancer dzine simba.

https://www.bioocus.com/news/promising-outcomes-of-cd7-car-t-therapy-combined-with-second-transplant-in-relapsed-t-all-lbl-patien/

4. Kurapa kweCAR-T kweB-Cell Acute Lymphoblastic Leukemia: Kushanda Kusina Kumboitika

Ongororo ichangobva kuitwa inoratidza kushanda kwakanaka kwekurapa kwe chimeric antigen receptor-T cell (CAR-T) mukurapa B-cell acute lymphoblastic leukemia (B-ALL). Yakaitwa pamwe chete neBIOOCUS neLu Daopei Hospital, tsvakiridzo iyi yakaratidza kuti varwere vakawanda vakawana kuregererwa kwakakwana, zvichiita kuti kurapa kweCAR-T kuve sarudzo inotungamira yekurapa iyi leukemia ine simba. Mhedzisiro inovimbisa inoratidza kugona kwekurapa kweCAR-T mukenza, zvichipa tariro kuvarwere nemhuri dziri kutarisana neB-ALL. Sezvo tsvakiridzo ichifambira mberi, kurapa kweCAR-T kwakagadzirirwa kuita basa rakakosha mune ramangwana rekurapa kenza.

https://www.bioocus.com/news/pioneering-car-t-therapy-in-b-cell-acute-lymphoblastic-leukemia-shows-unprecedented-efficacy/

Maitiro Ekurapa kweCAR-T

1.T-Cell Collection:

Pakutanga, vanachiremba vanounganidza masero eT kubva muropa remurwere vachishandisa nzira inonzi leukapheresis. Maitiro aya anowanzo tora maawa angangoita mana, panguva iyo muchina wekuparadzanisa ropa unobvisa masero machena eropa anodiwa wodzosera zvimwe zvikamu mumuviri wemurwere.

2. Kugadziriswa uye Kuwedzera kweMajini:

Masero eT akaunganidzwa anotumirwa kurabhoritari kuti anogadziriswa majini. Padanho iri, masero eT akagadzirwa kuti arwise nekuparadza masero egomarara. Izvi zvinotora mavhiki angangoita maviri kusvika matatu. Munguva iyi, masero eT anovhurwa uye anowedzerwa murabhoritari kuti ave nechokwadi chekuti anoshanda zvakanaka pakurwisa gomarara.

3. Kuiswa kwemasero:

Kana masero eT akagadzirwa agadzirira, anodzoserwa mumuviri wemurwere kuburikidza nekuiswa mutsinga. Danho iri rinobvumira masero ekudzivirira chirwere akagadziriswa kuti azive uye abvise masero ekenza zvinobudirira.

Varwere vanogona kusangana nemigumisiro panguva yekurapwa, iyo inowanzo kuve cytokine release syndrome (CRS), inokonzerwa nemhinduro yemuviri panguva yekuparadzwa kwemasero ekenza. Kunyangwe CRS ichigona kunge yakanyanya, kufambira mberi mukurapwa kwevarwere kwakaderedza zvakanyanya njodzi dzayo.

Nguva yese yekurapwa, kubva pakuunganidzwa kwemasero kusvika pakuiswa muropa, inowanzotora mavhiki mana kusvika matanhatu, kunyange hazvo nguva chaiyo ichienderana nemamiriro emurwere chaiwo.

Rutsigiro Rwakakwana rweVarwere Vekunze Kwenyika Vari Kufamba Kuenda kuBIOOCUS Kunorapwa neCAR-T

KuBIOOCUS, takazvipira kupa rubatsiro rwakasiyana-siyana uye rubatsiro kuvarwere vekune dzimwe nyika vari kutsvaga kurapwa kweCAR-T. Mabasa edu akazara anofukidza nhanho imwe neimwe yerwendo, kubva pakugadzirira rwendo kusvika pakutarisirwa mushure mekurapwa.

1. Kugadzirira Kufamba Usati Waenda

Vasati vaenda kuBIOOCUS, varwere vachaongororwa zvizere pachipatara chavanogara. Izvi zvinosanganisira kuongororwa kwakazara kwenhoroondo yezvekurapa, kuongororwa kwemuviri, uye bvunzo dzakakodzera dzakadai sekushanda kweropa, zvidzidzo zvemifananidzo, uye kuongororwa kwakanangana nerudzi rwekenza iri kurapwa (senge leukemia, lymphoma, kana mamwe magomarara eropa). Tinova nechokwadi chekuti zvinyorwa zvese zvekurapa, kusanganisira kurapwa kwakaitwa kare, mhedzisiro yebvunzo, uye kusimbiswa kwechirwere, zvinotumirwa kuchikwata chedu kuti zviongororwe uye zvigadziriswe.

2. Kufamba uye Kurapwa muchipatara

Tinobatsira mune zvese zvinodiwa pakufamba, kusanganisira kuronga pekugara uye kubhuka varwere vari muchipatara paBIOOCUS International Medical Center. Pavanosvika, varwere vanotungamirirwa nemaitiro ekugamuchirwa, zvichiita kuti vaende kunzvimbo yekurapwa zvakanaka.

3. Maitiro Ekurapa

Pavanopinda muchipatara, varwere vachaongororwa kakawanda, kusanganisira kuongororwa kuti vaone kana vakakodzera kurapwa neCAR-T. Izvi zvinosanganisira kuongororwa kwemamiriro egomarara remurwere uye hutano hwake, pamwe nekutorwa kweropa kuti ribviswe mumasero eT. Masero eT anounganidzwa anozotumirwa kurabhoritari yedu ine GMP-certified kuti agadziriswe majini. Maitiro aya anogona kutora mavhiki maviri kusvika matatu.

4. Kuiswa kwemasero uye Kutarisirwa mushure mekurapwa

Kana masero eCAR-T akagadziriswa agadzirwa, varwere vanodzokera kuchipatara chedu kuti vanopihwa mushonga wekuisa muropa. Uku kurapwa kamwe chete uko maT-cell akagadzirwa anopihwa nemutsinga. Mushure mekupihwa mushonga wekuisa muropa, varwere vacharamba vachitariswa kwemazuva akati wandei kuti vaone kana paine migumisiro yakaipa, yakadai se cytokine release syndrome, inova mhinduro inogona kuitika pakurapa. Chikwata chedu chekurapa chinopa rutsigiro nekutarisa nguva dzose munguva ino yakaoma.

Mushure mekubuda muchipatara, BIOOCUS inoronga kushanya kwekutevera nguva nenguva, kusanganisira bvunzo dzemurabhoritari nezvidzidzo zvemifananidzo, kuti vatarise kushanda kwekurapa uye vatarise kupora kwemurwere. Varwere vachatariswa zvakanyanya kuti vaone kana paine migumisiro yekurapa yanonoka, uye timu yedu icharamba ichitaurirana kuti ipe nhungamiro nerutsigiro zvinoenderera mberi.

KuBIOOCUS, tinokoshesa hutano, kuchengetedzeka, uye nyaradzo yevarwere vedu vekune dzimwe nyika. Chinangwa chedu ndechekupa rubatsiro rwakakwana uye kuona kuti vanowana rutsigiro uye ruzivo rwakakwana murwendo rwese rwekurapwa kweCAR-T.

Kuti uwane rumwe ruzivo nezvemabasa edu uye kuti tingakubatsira sei nekurapwa kwako, ndapota taura nesu zvakananga.

tsananguro2

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.